Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial
Oral fluoropyrimidines, such as S-1, have been shown to have a role in controlling disease progression in metastatic breast cancer. We did a multicentre, open-label, randomized, controlled, phase 3 trial in 139 sites. Eligible patients were women aged 20–75 years with stage I to IIIB invasive breast cancer. As the primary endpoint was met, the trial was terminated early.
